Avid Bioservices Inc (CDMO)

[Protector]

JJ1223, the most positive they may have to say is that they entered a deal with AstraZeneca who has PD and CTLA pipelines in I-O and by acquisition several other I-O candidates and that they start combining with Bavituximab and set everything on COMBO's in those big market solid cancers for with AZ is hopelessly behind on BMY and MERCK.

Furthermore, and actuqlly that came out of a discussion with someone here in the US this week-end, there is another thing that I, and unless it is somewhere in the last 1500 posts of which I missed many, and nobody else on this board ever tough.

AstraZeneca must not just fight back to gain a meaningful position, #1, in the I-O market by moving into combo's because that is the only way they will beat the PD and CTLA alone programs. They must ALSO make sure they move FAST because ROCHE has the SAME problem then AstraZeneca.

They must ALSO fight back and they ALSO know that AstraZeneca goes combo's (AW PRed it). So there is a RACE between ALL 4 to be first with Combo's while BMY and Merck will have REVENUE out of I-O already and are creating a market.

So IF (and that is an IF) there would be partnering news then while for US it would be evidence itself that it would be AstraZeneca, we must take into account that the others could want to scoop the possible power drugs like Bavituximab away before AZ's nose.

Actually that is what I would do to handicap competitions. As said before, there are at 4 players that TODAY have production of PD and CTLA based drugs that a Biotech can go to to combine, but there is only ONE Bavituximab.